10.1 C
London
Friday, March 22, 2024
HomeCoronavirusNovavax signs COVID-19 vaccine supply deal with Serum Institute

Novavax signs COVID-19 vaccine supply deal with Serum Institute

Date:

Related stories

Intermittent fasting can lead to cardiovascular diseases, says study

Fatty foods, sugars, and junk food, seem very unhealthy,...

‘The Iceman’ Wim Hof’s cold exposure therapy has benefits: Study

A recent study has shed light on the potential...

Slowed speech potential indicator of cognitive decline, says study

The study, conducted by researchers at the University of...

Menstrual health literacy is alarmingly low, says study

Research conducted by biologist Deena Emera where she talks...

NHS to stop prescription of puberty blockers following safety concerns

National Health Services (NHS) England has recently announced a...

Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.

The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.

The deal was signed on July 30, according to an SEC filing by Novavax.

On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories